Wednesday, June 2, 2010

Oramed Pharmaceuticals Forms Joint Venture - Launches Entera Bio Ltd.

Link to News Release: http://finance.yahoo.com/news/Oramed-Pharmaceuticals-Forms-prnews-1919477739.html?x=0&.v=1



Oramed Pharmaceuticals Inc. (OTCBB:ORMP.ob - News), a developer of oral drug delivery systems, announced today that its subsidiary Oramed Ltd. entered into a joint venture agreement with Laser Detect Systems Ltd. ("Laser Detect"), an Israeli company listed on the Tel Aviv Stock Exchange, for the establishment of a new company to be called Entera Bio Ltd. ("Entera"). Under the terms of the agreement, Oramed will out-license technology to Entera for the development of oral delivery drugs for certain indications. The out-licensed technology differs from Oramed's main delivery technology that is used for oral insulin and is subject to a different patent application. Entera's initial development effort will be an oral formulation for the treatment of osteoporosis.

Dr. Phillip Schwartz will serve as Entera's Chief Executive Officer. Dr. Schwartz has over 10 years of experience in the pharmaceutical and biotech industries and served as a lecturer at Harvard Medical School. Prior to joining Entera, Dr. Schwartz served as the Scientific and Medical Development Manager for Endo Pharmaceuticals (NasdaqGS:ENDP - News).

Nadav Kidron, Chief Executive Officer of Oramed Pharmaceuticals, commented, "This joint venture affords an opportunity to explore a technology with different characteristics from Oramed's main technology, which has the potential to make a significant contribution in the oral drug delivery arena. We look forward to a successful relationship with Laser Detect and Entera."

According to the agreement, Laser Detect will invest $600,000 in Entera, and Entera will be owned in equal parts by Oramed and Laser Detect. Entera's Chief Executive Officer will be granted options to purchase ordinary shares of Entera, reflecting 9.9% of the Entera's share capital, immediately following the dilution by these options. Entera's board of directors will be comprised of four members - one director designated by each of Oramed and Laser Detect, Dr. Schwartz and Mr. Kenneth Abramowitz, co-founder and Managing General Partner of NGN Capital.

Mr. Zeev Bronfeld, who is one of Laser Detect's controlling shareholders, is also an affiliated shareholder of Oramed Pharmaceuticals Inc. Accordingly, the closing of the transaction is subject to the approval of Laser Detect's shareholders.

For more information about Oramed's clinical development programs, please visit http://www.oramed.com.



Safe Harbor Statement

Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risk that the transaction will not be approved by the shareholders of Laser Detect, the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; Entera's ability to obtain additional funding required to conduct its research, development and commercialization activities; and Oramed's ability to maintain a significant equity stake in Entera. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking statements. The company undertakes no obligation to update or revise any forward-looking statements.


Company Address

Oramed, Inc.

Tara Horn

Hi-Tech Park 2/5 Givat Ram
PO Box 39098
Jerusalem, 91390, Israel

T U.S. 1-646-240-4193Israel +972-2-566-0001Fax +972-2-566-0004

Investor Relations

Emerging Markets Consulting, LLC.

Web Address:
www.emergingmarketsllc.com

Contact Us:
(321) 206-6682
126 S. Bumby Ave. Suite A
Orlando, FL 32803

Disclaimer: Emerging Markets Consulting, LLC (“EMC”) prepares and/or assists others in preparing and publishing oral and written information on selected companies (the “Profiled Companies”) and/or their securities (the “Securities”) in various contexts, including but not limited to corporate and business profiles, summaries, reports, and press releases (hereafter referred to as the “Corporate Information”) through various methods including but not limited to: (a) facsimile; (b) email; (c) mail and courier; (d) world wide web, including but not limited to EMC’s website at www.emergingmarketsllc.com; and (e) personal contact at trade shows, business luncheons, seminars and/or meetings. The Corporate Information may be disseminated to broker-dealers, members of the general public, and the financial community (collectively the “Recipients”) at the direction of the Profiled Companies and should be used by the Recipients for informational purposes only.

EMC and/or its principals, affiliates and representatives receive cash and/or compensation in the Securities in connection with preparation and dissemination of the Corporate Information. EMC did not pay cash consideration for the Securities that it holds (other than payments that may be made by EMC to the Profiled Companies for the exercise of warrants), and any of the Securities held by EMC were issued in exchange for EMC’s services. Because EMC is a Shareholder of the Profiled Companies, EMC may have a conflict of interest with the Recipients as well as the Profiled Companies. Independent of any compensation that EMC and/or its principals, affiliates, and representatives may receive, EMC and/or its principals, affiliates, and representatives may at any time purchase and/or sell the Securities, including simultaneous with the publication or distribution of the Corporate Information. The buying and selling of the Securities by EMC and/or its principals, affiliates, and representatives may negatively effect the price of the Securities or cause the price of the securities to increase or decrease or become unstable.

EMC does not express any opinions, recommendations or viewpoints regarding the Profiled Companies or the Securities, and has not conducted due diligence of any data or information contained in the Corporate Information. The Corporate Information is based solely upon data and information provided by the Profiled Companies and EMC does not endorse, independently verify, or assert the truthfulness, completeness, accuracy or reliability of the Corporate Information. EMC conducts no due diligence of any type of the Profiled Companies or the Securities. Recipients should not rely on the data or information contained in the Corporate Information in making an investment decision and should conduct their own research of the Profiled Companies. The Recipients should not assume that material changes have not occurred since the publication and/or dissemination of in the Corporate Information. Each of the Recipients should consult with his or her legal, accounting, tax and financial advisers regarding any investment in the Profiled Companies or the Securities.

EMC is not a registered investment advisor or registered securities broker dealer and no information contained within the Corporate Information should be construed as investment advice or as a solicitation to offer, purchase or sell the Securities. The Securities may be thinly traded and not listed on any national securities exchange and involve an extremely high degree of risk. Because the Securities are penny stocks, they are subject to the Securities and Exchange Commission's penny stock rules, and as such, any investment in the Securities involves a high degree of risk and it may be difficult for any investor or Shareholder to resell the Securities. An investment in the Securities could result in the loss of some or all of an investment.

Recipients should (with the assistance of their legal and financial advisors) review Securities and Exchange Commission (“SEC”) filings regarding the Profiled Companies that are SEC reporting issuers. These SEC filings are available for review at www.sec.gov. Recipients should review investment guides that are available at the same SEC website and the National Association of Security Dealers website at www.nasd.com.

Statements contained in the Corporate Information that are not historical facts are forward looking statements that involve risks and uncertainties and may be identified by the use of terminology such as “believes”, “expects”, “may”, “will”, or “should”, or “anticipates”. Such statements should be read as being applicable to all related forward looking statements wherever they appear in any of the Corporate Information. The actual results of a Profiled Company’s operations, financial condition or other aspects of its business could differ materially from those discussed in the Corporate Information.

The issuance of the Securities to EMC may cause shareholders and/or investors of the Profiled Companies to experience immediate and substantial dilution of their holdings and/or investments in the Profiled Companies. Future securities issuances to EMC for services may also result in a reduction of (i) the book value or market price of the Profiled Companies’ securities, (ii) shareholder voting power; and (iii) each shareholder’s proportionate ownership of any Profiled Company.

Section 17(b) of the Securities Act of 1933 requires that any person that uses the mails to publish, give publicity to, or circulate any publication or communication that describes a security in return for consideration received or to be received directly or indirectly from an issuer, underwriter, or dealer, must fully disclose the type of consideration (i.e. cash, free trading stock, restricted stock, stock options, stock warrants) and the specific amount of the consideration. In connection therewith, EMC has received the following compensation and/or has an agreement to receive in the future certain compensation, as described below:

Disclaimer EMC has a December 16, 2009 contract to provide Investor Relations services for Oramed Pharmaceuticals for a six month period. The company is to pay EMC 100,000 restricted shares of Stock and $5,000 monthly. EMC has been paid $35,000 and 100,000 restricted shares. View full disclaimer at http://server1.streamsend.com/streamsend/clicktracker.php?cd=5119&ld=2&md=209&ud=abc90c6eee3041cdd572857428e5a03f&url=http://www.emergingmarketsllc.com/disclaimer.php

News Alert BCLI

BrainStorm To Present at Inaugural Stem Cell Conference Hosted by National Securities Corporation and MD Becker Partners


Link to News Release: http://finance.yahoo.com/news/BrainStorm-To-Present-at-bw-2460625924.html?x=0&.v=1

BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI - News), a leading developer of adult stem cell technologies and therapeutics today announced that Rasheda Ali, a member of BrainStorm’s advisory board and Professor Eldad Melamed, BrainStorm’s Chief Medical Advisor, will be presenting at today's Inaugural Stem Cell Investor and Executive Networking Conference Event from 11:00 a.m. to 4:00 p.m. (EDT), at National Securities Corporation Global Headquarters at 120 Broadway, (2nd Floor Conference Center) in New York City.

At the conference, Rasheda Ali, the revered author and daughter of renowned boxer Muhammad Ali, will provide remarks at 11:00 AM and discuss BrainStorm and its upcoming ALS clinical trials.

Professor Eldad Melamed, the former Head of Neurology, Rabin Medical Center, and Tel-Aviv University, and a member of the Scientific Committee of the Michael J. Fox Foundation for Parkinson's Research, will panel a session titled “Autologous Approaches” at 2:00 PM discussing BrainStorm’s approach to treating ALS patients.

The Stem Cell Investor & Executive Networking Conference Event, hosted by National Securities Corporation and MD Becker Partners, is strategically designed to unite investors with industry executives to exchange information and highlight opportunities in the expanding stem cell universe. The event will bring together the founding visionary researchers, clinicians, entrepreneurs, key investors, and other stakeholders to offer compelling panel discussions, share information, and discuss the future of the field. For more information on the conference please go tohttp://www.mdbpartners.com/science.

About BrainStorm Cell Therapeutics, Inc.

BrainStorm Cell Therapeutics Inc. is an emerging company developing adult stem cell therapeutic products, derived from autologous (self) bone marrow cells, for the treatment of neurodegenerative diseases. The patent pending technology is based on discoveries made by the scientific team led by Professor Eldad Melamed, former Head of Neurology at Rabin Medical Center, and cell biologist Prof. Daniel Offen, Head of the Neuroscience Laboratory at the Felsenstein Medical Research Center of Tel-Aviv University. The technology allows for the differentiation of bone marrow-derived stem cells into functional neurons and astrocytes, as demonstrated in animal models. The Company holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel-Aviv University. The Company's current focus is on ALS, although its technology has promise for treating several other diseases including MS, Huntington's disease and stroke.

Safe Harbor Statement

Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. The potential risks and uncertainties include risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. The Company does not undertake any obligation to update forward-looking statements made by us.

Contact:

BrainStorm Cell Therapeutics
Rami Efrati, CEO, +972-3-9236384
efrati@brainstorm-cell.com




Company:
BrainStorm
Symbol:
OTCBB:BCLI





Secret #1.
Buy low, sell high

Secret #2.
Be fearful when others are greedy and greedy when others are fearful

Secret #3.
Buy when there’s blood in the streets



Disclaimer

Emerging Markets Consulting, LLC (“EMC”) prepares and/or assists others in preparing and publishing oral and written information on selected companies (the “Profiled Companies”) and/or their securities (the “Securities”) in various contexts, including but not limited to corporate and business profiles, summaries, reports, and press releases (hereafter referred to as the “Corporate Information”) through various methods including but not limited to: (a) facsimile; (b) email; (c) mail and courier; (d) world wide web, including but not limited to EMC’s website at www.emergingmarketsllc.com; and (e) personal contact at trade shows, business luncheons, seminars and/or meetings. The Corporate Information may be disseminated to broker-dealers, members of the general public, and the financial community (collectively the “Recipients”) at the direction of the Profiled Companies and should be used by the Recipients for informational purposes only.

EMC and/or its principals, affiliates and representatives receive cash and/or compensation in the Securities in connection with preparation and dissemination of the Corporate Information. EMC did not pay cash consideration for the Securities that it holds (other than payments that may be made by EMC to the Profiled Companies for the exercise of warrants), and any of the Securities held by EMC were issued in exchange for EMC’s services. Because EMC is a Shareholder of the Profiled Companies, EMC may have a conflict of interest with the Recipients as well as the Profiled Companies. Independent of any compensation that EMC and/or its principals, affiliates, and representatives may receive, EMC and/or its principals, affiliates, and representatives may at any time purchase and/or sell the Securities, including simultaneous with the publication or distribution of the Corporate Information. The buying and selling of the Securities by EMC and/or its principals, affiliates, and representatives may negatively effect the price of the Securities or cause the price of the securities to increase or decrease or become unstable.

EMC does not express any opinions, recommendations or viewpoints regarding the Profiled Companies or the Securities, and has not conducted due diligence of any data or information contained in the Corporate Information. The Corporate Information is based solely upon data and information provided by the Profiled Companies and EMC does not endorse, independently verify, or assert the truthfulness, completeness, accuracy or reliability of the Corporate Information. EMC conducts no due diligence of any type of the Profiled Companies or the Securities. Recipients should not rely on the data or information contained in the Corporate Information in making an investment decision and should conduct their own research of the Profiled Companies. The Recipients should not assume that material changes have not occurred since the publication and/or dissemination of in the Corporate Information. Each of the Recipients should consult with his or her legal, accounting, tax and financial advisers regarding any investment in the Profiled Companies or the Securities.

EMC is not a registered investment advisor or registered securities broker dealer and no information contained within the Corporate Information should be construed as investment advice or as a solicitation to offer, purchase or sell the Securities. The Securities may be thinly traded and not listed on any national securities exchange and involve an extremely high degree of risk. Because the Securities are penny stocks, they are subject to the Securities and Exchange Commission's penny stock rules, and as such, any investment in the Securities involves a high degree of risk and it may be difficult for any investor or Shareholder to resell the Securities. An investment in the Securities could result in the loss of some or all of an investment.

Recipients should (with the assistance of their legal and financial advisors) review Securities and Exchange Commission (“SEC”) filings regarding the Profiled Companies that are SEC reporting issuers. These SEC filings are available for review at www.sec.gov. Recipients should review investment guides that are available at the same SEC website and the National Association of Security Dealers website atwww.nasd.com.

Statements contained in the Corporate Information that are not historical facts are forward looking statements that involve risks and uncertainties and may be identified by the use of terminology such as “believes”, “expects”, “may”, “will”, or “should”, or “anticipates”. Such statements should be read as being applicable to all related forward looking statements wherever they appear in any of the Corporate Information. The actual results of a Profiled Company’s operations, financial condition or other aspects of its business could differ materially from those discussed in the Corporate Information.

The issuance of the Securities to EMC may cause shareholders and/or investors of the Profiled Companies to experience immediate and substantial dilution of their holdings and/or investments in the Profiled Companies. Future securities issuances to EMC for services may also result in a reduction of (i) the book value or market price of the Profiled Companies’ securities, (ii) shareholder voting power; and (iii) each shareholder’s proportionate ownership of any Profiled Company.

Section 17(b) of the Securities Act of 1933 requires that any person that uses the mails to publish, give publicity to, or circulate any publication or communication that describes a security in return for consideration received or to be received directly or indirectly from an issuer, underwriter, or dealer, must fully disclose the type of consideration (i.e. cash, free trading stock, restricted stock, stock options, stock warrants) and the specific amount of the consideration. In connection therewith, EMC has received the following compensation and/or has an agreement to receive in the future certain compensation, as described below:

EMC has been paid: 1,250,000 Shares of BCLI from BrainStorm Cell for preparation and distribution of this report. Do not invest in any stocks profiled unless you can lose your entire investment.